Can a drug shrink precancerous breast cells before surgery?

NCT ID NCT02928978

Completed Disease control Sponsor: Julie Nangia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a drug called ruxolitinib can reduce abnormal breast cells in people with high-risk or precancerous breast conditions like DCIS or atypical hyperplasia. Half of the 84 participants took ruxolitinib for about 15 days before surgery, and the other half took a placebo. Researchers compared cell death in breast tissue samples taken before and after treatment to see if the drug had an effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL DUCTAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical lobular breast hyperplasia breast carcinoma in situ breast intraductal proliferative lesion ductal breast carcinoma in situ lobular breast carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATYPICAL DUCTAL HYPERPLASIA ATYPICAL LOBULAR HYPERPLASIA DUCTAL CARCINOMA IN SITU LOBULAR CARCINOMA IN SITU

Contacts and locations

Locations

Harris Health System - Smith Clinic

Houston, Texas, 77054, United States
Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Montefiore Medical Center

The Bronx, New York, 10461, United States
O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77054, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.